Header

Three business people meeting in a room

Awards and Recognition

Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.

Elderly woman visits the doctor's clinic for a medical check-up

People and society

We believe our people are our greatest asset, while building trust with society is a key pillar of the Novartis corporate strategy and critical to delivering on our purpose of reimagining medicine.

Novartis included again in the 2023 Bloomberg Gender-Equality Index
CDP upgrades Novartis to A in CDP Climate Change and CDP Water in 2022
Novartis recognized as Stonewall Top Global Employer 2022 with Silver Award

Group of business people watching at a screen using special glasses

Innovation and digital

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues.

Novartis wins a Reuters Responsible Business Award for the Novartis in Society Integrated Report
Novartis enters the Top 50 Most Innovative Companies list by Boston Consulting Group
Novartis was included in Fortune’s World’s Most Admired Companies list

More awards

People and society
Innovation and digital

People and society

We are proud to be included, for the fourth consecutive year, in the 2023 Bloomberg Gender-Equality Index which reflects our continuing commitment to gender equity and inclusion at Novartis.

Novartis is proud to be a double-A list company after a CDP upgrade to A (Leadership) in both CDP Climate Change and CDP Water Security in 2022.

As part of our ongoing commitment to LGBTQI equity, we’re proud to be recognized as a Stonewall Top Global Employer 2022, with Silver Award. This award reflects the huge strides we’ve made as a company over the past few years toward creating a more equitable and inclusive work environment for our LGBTQI community around the world.

Novartis was once again included in the Fortune World's Most Admired Companies list, gaining a score of 7.5 (2021: 7.4) in the survey. This year, over 3 700 executives, directors and analysts completed the survey, with a total of 640 companies across 28 countries participating. Novartis ranked #5 in the pharmaceuticals industry list.

We are proud to be included, for the third consecutive year, in the 2022 Bloomberg Gender-Equality Index which reflects our continuing commitment to gender equity and inclusion at Novartis.

Paying tribute to those who stood up to the mark in a time of trouble and made a real impact within the community in terms of supporting them through the pandemic.

The Association for Talent Development (ATD)’s BEST Award is the talent development industry’s most rigorous and coveted recognition. The global program recognizes organizations that demonstrate enterprise-wide success through talent development.

Novartis is proud to be included in Fortune’s World’s Best Workplaces™ 25-company list. Separately, Novartis has been included in the Best Workplaces National Award Lists of Brazil, Canada, Chile, Nigeria, Spain and Turkey, with 93% of surveyed employees saying Novartis is a great place to work. We value being ranked among the world’s top workplaces, as we consistently enhance our people's work experience by transforming our culture to be more Inspired, Curious and Unbossed.

Forbes teamed up with market research company Statista to identify the companies most liked by new workforce entrants in their annual ranking. The list was compiled by surveying 20 000 Americans with less than 10 years professional experience working for businesses with at least 1 000 employees.

We are honored to have been certified as a Top Employer globally, the first time our worldwide organization has earned this distinction. This certification will encourage the continued attraction of top talent to our organization and strengthen our offering as a destination employer into the future.

Novartis rose to #3 in the Fortune World's Most Admired Companies Pharmaceuticals Industry list, from #4 in 2020 and 2019. Across the scored reputational dimensions, Novartis saw significant improvements in Social Responsibility (ranking as #4 most admired pharma company in this category in 2021 vs #8 in 2020) and Quality of Products (#4 in 2021 vs #7 in 2020). Novartis ranks #3 in Innovation and #2 In Global Competitiveness (the same as 2020).

Novartis is proud to be included again in the 2021 Bloomberg Gender-Equality Index. We are honored to be recognized among the 380 companies that achieve the highest standards in measures of inclusion such as female empowerment and gender pay parity, across 44 countries and regions. This further supports our commitment to build an inclusive and equitable workplace that empowers all of our associates to achieve their full potential.

Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

Novartis is one of 106 companies worldwide to make CDP’s Water A List in 2020. We also maintained an A- rating and are recognized among category leaders in the 2020 CDP Climate Score.

Novartis is pleased to be included in the Dow Jones Sustainability World Index and the DJSI Europe Index again this year. We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital development and labor practices.

We are proud to have received a learning award from the Learning and Performance Institute, who are known for recognizing the highest achievements in the workplace around learning and development.

At Novartis, we seek to build a diverse and inclusive workplace that values unique and curious minds, where we are all free to be our best and true selves. We are proud therefore to be recognized in the Refinitiv Top 25 Most Diverse & Inclusive Companies for the third year in a row. This reflects our continued commitment to listen to different communities with a learning mindset and shape business practices that contribute to building a world that is healthier, safer and more inclusive.

Novartis is proud to announce its inclusion in the 2020 Bloomberg Gender-Equality Index! We are honored to be recognized among 325 companies across 50 industries and 42 countries and regions. This reflects our commitment to fostering a more inclusive and equitable workplace and our continued work toward achieving gender balance in management and positively influencing the gender pay gap by 2023.

Novartis has again been ranked #4 by Fortune Magazine as one of the most admired pharmaceutical companies in the world.

We are proud to have been recognized by the Association of Talent Development and to receive the Excellence in Practice Award in 2019 for our commitment to developing talent.

We are delighted to have received the bronze award for the Excellence in Partnership honor for our work with Learnlight that has led to the implementation of a new virtual language training solution.

We are delighted to be recognized for our efforts as we continue to go big on learning.

We are delighted and thankful to our associates to be listed one of the top 20 employers after completing the 17th Annual Top Employer Survey by Science Magazine.

Most attractive Employers Award 2019 goes to Novartis Switzerland. We are proud to have been voted as the most attractive employer in the field of natural science by students in the annual Universum survey.

The Corporate Reputation of Pharma 2019 global report reflects the findings of a survey conducted by PatientView with patient organizations worldwide.

Novartis is one of 71 companies worldwide to make CDP’s Water A List in 2019. We also maintained an A- rating and are recognized among category leaders in the 2019 CDP Climate Score.

Novartis is pleased to be included in the Dow Jones Sustainability World Index and the DJSI Europe Index again this year. We are proud of our industry-leading performance in the areas of environmental reporting, environmental policy and management systems, and labor practices.

In PatientView’s 2018 “Corporate Reputation of the Pharmaceutical Industry – from the Patient Perspective” Novartis ranked #4 overall. The company was also the number one partner for patient groups and ranked first in corporate brand awareness.

The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using up to 14 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.

We moved up one position from number 3 in 2016, in recognition of our efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice.

Our 2017 Corporate Responsibility Report was awarded by Ethical Corporation, a nongovernmental organization that recognizes those that are truly having an impact on business, society and the environment.

Novartis is pleased to be included in the Dow Jones Sustainability World Index and the DJSI Europe Index again this year. We are proud of our industry-leading performance in the areas of governance, environmental reporting, environmental policy and management systems, and human capital development.

Novartis has been ranked #2 out of the top 100 publicly traded companies that make up the Thomson Reuters Diversity & Inclusion Index. As one of the most diverse and inclusive workplaces globally, we are proud that our efforts to create an environment where everyone feels valued, respected and heard are being recognized.

The Nature Index 2018 ranking, published by Nature Research, ranks various institutions (corporate, academic, government, NPO/NGO) based on contributions to articles published in a group of 82 selected science journals. Novartis maintained its #3 ranking from 2017.

The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using up to 14 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.

Novartis is one of 73 companies worldwide to make CDP’s Water A List in 2017. We also maintained an A- rating and are recognized among category leaders in healthcare in the 2017 CDP Climate Score.

Novartis ranked #4 in Fortune’s list of companies that are doing well by doing good. The list recognizes companies that have a positive social impact through activities that are part of their core business strategy.

Novartis was ranked fourth in the 2017 Dow Jones Sustainability Index (DJSI) World (up from 7th in 2016), and re-entered the DJSI Europe Index for the first time in four years.

The FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.

Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list. This is the third consecutive year that Novartis ranked as the second-most-admired company in our sector, and the 13th consecutive year that Novartis is in the top three.

The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using up to 14 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.

Novartis ranked sixth among the Top 100 ranked companies of Thomson Reuters’ “IX Global Diversity and Inclusion Index.

Innovation and digital

The Novartis in Society Integrated Report 2021 wins in the Reporting and Transparency category, with judges saying it ”demonstrates how businesses can go beyond the current paradigm, setting an encouraging standard for future reporting practices for all businesses”.

Novartis was once again included in the Fortune World's Most Admired Companies list, gaining a score of 7.5 (2021: 7.4) in the survey. This year, over 3 700 executives, directors and analysts completed the survey, with a total of 640 companies across 28 countries participating. Novartis ranked #5 in the pharmaceuticals industry list.

Paying tribute to those who stood up to the mark in a time of trouble and made a real impact within the community in terms of supporting them through the pandemic.

Novartis rose to #3 in the Fortune World's Most Admired Companies Pharmaceuticals Industry list, from #4 in 2020 and 2019. Across the scored reputational dimensions, Novartis saw significant improvements in Social Responsibility (ranking as #4 most admired pharma company in this category in 2021 vs #8 in 2020) and Quality of Products (#4 in 2021 vs #7 in 2020). Novartis ranks #3 in Innovation and #2 In Global Competitiveness (the same as 2020).

Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

Novartis is proud to be named one of the “Top 50 Most Innovative Companies in the World” by Boston Consulting Group. The list ranks companies based on a global survey of executives as well as the return they have produced for shareholders over the past three years.

We are delighted to be recognized for our efforts as we continue to go big on learning.

Novartis has again been ranked #4 by Fortune Magazine as one of the most admired pharmaceutical companies in the world.

IdeaPharma’s PII ranks companies on their ability to bring products from early development to market and commercialize them successfully. Novartis moved up 9 spots, from #12 in 2017.

Novartis has been named #1 most innovative biotech company and ranked #21 overall by Fast Company. The ranking identifies the most notable innovations of the year.

Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list. This is the third consecutive year that Novartis ranked as the second-most-admired company in our sector, and the 13th consecutive year that Novartis is in the top three.

Novartis is again honored to be included in the 2017 “Top 10 Pipelines” list published by MedAdNews.

Our approach to rankings and ratings (PDF 0.1 MB)

AddToAny buttons

Share Tweet Share Whatsapp Linkedin Email

Printable Links Block (Content)